Back to search

Article

Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients

2023-11-26

Abstract excerpt

The development of tyrosine kinase inhibitors (TKIs) has dramatically improved the treatment outcomes of the chronic myelogenous leukemia-chronic phase (CML-CP). However, cardiovascular events (CVEs), such as hypertension, peripheral arterial occlusive disease, pulmonary arterial hypertension, and cerebral infarction, continue to occur, which highlights the need to develop preventive monitoring and treatment strat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8489fcfd-c0ee-5a4b-9fee-5d8839ddffec
DOI
10.21203/rs.3.rs-3632503/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patientsDOI 10.21203/rs.3.rs-3632503/v1
The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemiaSemantic proximity
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSemantic proximity
Cardiovascular disease after hematopoietic cell transplantation - lessons learnedSemantic proximity
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agentsSemantic proximity
Management of Carfilzomib-Associated Cardiac Adverse Events.Semantic proximity
Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity
Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplantSemantic proximity
Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity
HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaSemantic proximity
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.Semantic proximity
Select a neighboring publication to make it the new centre.